What You Need to Know Ahead of McKesson Corporation's Earnings Release

Core Insights - McKesson Corporation (MCK) is valued at a market cap of $101.7 billion and operates in healthcare services and information technology, focusing on the distribution of pharmaceuticals and medical supplies, as well as offering healthcare IT solutions [1] Financial Performance - Analysts expect MCK to report a profit of $9.19 per share for fiscal Q3 2026, representing a 14.5% increase from $8.03 per share in the same quarter last year [2] - For fiscal 2026, MCK is projected to report a profit of $38.61 per share, up 16.8% from $33.05 per share in fiscal 2025, with further growth expected to $43.53 per share in fiscal 2027, a year-over-year increase of 12.7% [3] Stock Performance - MCK shares have increased by 38% over the past 52 weeks, significantly outperforming the S&P 500 Index's 17% return and the State Street Health Care Select Sector SPDR ETF's 12.6% increase during the same period [4] - Following the release of impressive Q2 results, MCK's shares surged by 1.7% in the subsequent trading session, with overall revenue rising 10.1% year-over-year to $103.2 billion and adjusted EPS increasing by 39.5% from the previous year [5] Analyst Ratings - Wall Street analysts maintain a highly optimistic outlook on MCK's stock, with a "Strong Buy" rating from 13 out of 17 analysts, while four analysts suggest a "Hold" rating. The mean price target for MCK is $940.94, indicating a potential upside of 15.5% from current levels [6]